NCT00517192 - Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2008

Conditions

HIV Infections

Interventions

DRUG

Tipranavir

DRUG

Darunavir

DRUG

Ritonavir

Trial Locations (54)

Unknown

1182.71.1109 Boehringer Ingelheim Investigational Site, Beverly Hills

1182.71.1101 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1182.71.1104 Boehringer Ingelheim Investigational Site, Miami

1182.71.1115 Boehringer Ingelheim Investigational Site, Miami

1182.71.1108 Boehringer Ingelheim Investigational Site, Tampa

1182.71.1126 Boehringer Ingelheim Investigational Site, Charlotte

1182.71.1124 Boehringer Ingelheim Investigational Site, Portland

1182.71.1116 Boehringer Ingelheim Investigational Site, Houston

1182.71.1118 Boehringer Ingelheim Investigational Site, Longview

1182.71.3202 Boehringer Ingelheim Investigational Site, Brussels

1182.71.3203 Boehringer Ingelheim Investigational Site, Brussels

1182.71.3205 Boehringer Ingelheim Investigational Site, Brussels

1182.71.3206 Boehringer Ingelheim Investigational Site, Charleroi

1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver

1182.71.1001 Boehringer Ingelheim Investigational Site, Ottawa

1182.71.1003 Boehringer Ingelheim Investigational Site, Montreal

1182.71.1006 Boehringer Ingelheim Investigational Site, Montreal

1182.71.1010 Boehringer Ingelheim Investigational Site, Montreal

1182.71.3305A Boehringer Ingelheim Investigational Site, Bondy

1182.71.3303A Boehringer Ingelheim Investigational Site, Garches

1182.71.3301A Boehringer Ingelheim Investigational Site, Lyon

1182.71.3312A Boehringer Ingelheim Investigational Site, Lyon

1182.71.3306A Boehringer Ingelheim Investigational Site, Paris

1182.71.3308A Boehringer Ingelheim Investigational Site, Paris

1182.71.3310A Boehringer Ingelheim Investigational Site, Tourcoing

1182.71.4902 Boehringer Ingelheim Investigational Site, Berlin

1182.71.4907 Boehringer Ingelheim Investigational Site, Frankfurt

1182.71.4903 Boehringer Ingelheim Investigational Site, Mainz

1182.71.3002 Boehringer Ingelheim Investigational Site, Athens

1182.71.3003 Boehringer Ingelheim Investigational Site, Athens

1182.71.3001 Boehringer Ingelheim Investigational Site, Piraeus

1182.71.3912 Boehringer Ingelheim Investigational Site, Antella (fi)

1182.71.3901 Boehringer Ingelheim Investigational Site, Brescia

1182.71.3908 Boehringer Ingelheim Investigational Site, Florence

1182.71.3916 Boehringer Ingelheim Investigational Site, Palermo

1182.71.3907 Boehringer Ingelheim Investigational Site, Pavia

1182.71.3919 Boehringer Ingelheim Investigational Site, Pescara

1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora

1182.71.3504 Boehringer Ingelheim Investigational Site, Lisbon

1182.71.3503 Boehringer Ingelheim Investigational Site, Porto

1182.71.1129 Boehringer Ingelheim Investigational Site, Ponce

1182.71.3401 Boehringer Ingelheim Investigational Site, Barcelona

1182.71.3402 Boehringer Ingelheim Investigational Site, Barcelona

1182.71.3403 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat

1182.71.3405 Boehringer Ingelheim Investigational Site, Madrid

1182.71.3407 Boehringer Ingelheim Investigational Site, Madrid

1182.71.3408 Boehringer Ingelheim Investigational Site, Santiago de Compostela

1182.71.6604 Boehringer Ingelheim Investigational Site, Bangkok

1182.71.6601 Boehringer Ingelheim Investigational Site, Bangkok Noi

1182.71.6605 Boehringer Ingelheim Investigational Site, Chiang Mai

1182.71.6602 Boehringer Ingelheim Investigational Site, Khon Kaen

1182.71.6606 Boehringer Ingelheim Investigational Site, Nonthaburi

1182.71.6603 Boehringer Ingelheim Investigational Site, Phathumwan

1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau